Aurobindo Pharma’s US arm is recalling 47,040 bottles of Venlafaxine Hydrochloride extended release capsules, manufactured by the Hyderabad-based firm, from the American market. Venlafaxine hydrochloride extended-release capsules are indicated for the treatment of major depressive disorder.
Aurobindo Pharma USA Inc is recalling 47,040 bottles of Venlafaxine Hydrochloride extended release capsules in the strength of 37.5 mg in a nationwide recall in the US. As per the United States Food and Drug Administration (USFDA) the recall is on account of failed tablet/capsule specifications: some bottles contain punctured, and/or clumped /melted capsules.
The voluntary ongoing recall is a Class II recall. According the FDA, a class II recall is initiated in a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1831.30 |
| Dr. Reddys Lab | 1307.00 |
| Cipla | 1361.00 |
| Zydus Lifesciences | 940.10 |
| Lupin | 2460.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: